EliLilly has entered a strategic partnership with Radionetics Oncology, a biotechnology company focusing on the discovery and development of targeted radiopharmaceuticals to treat a broad range of solid tumors.
As part of the agreement, EliLilly will pay $140 million upfront to Radionetics Oncology with the goal of advancing the company’s pipeline of drug candidates. EliLilly also obtained the exclusive rights to acquire Radionetics for $1 billion after an exercise period concludes.
During this exercise period, Radionetics will continue building and developing its pipeline of small molecule radioligands. This therapeutic modality, consisting of hitching a radioactive isotope to a small molecule, is designed to selectively kill cancer cells with radiation while minimizing harm to healthy cells.
The company takes a “fit-for-purpose” approach that consists of pinpointing the precise target and selecting the ideal small molecule ligand paired with the optimal radioisotope to achieve a therapeutic effect.
“Our platform uniquely pairs the power of radiopharmaceuticals with the precision of small molecule targeting to novel GPCRs. We have a specialized team that is focused on rapidly advancing each of our promising programs to bring these much-needed new therapies to patients,” said Brett Ewald, Chief Operating Officer of Radionetics Oncology.
For EliLilly, the partnership with Radionetics Oncology is another step in its expansion into radiopharmaceuticals. In May this year, Lilly entered a partnership worth up to $1.1 billion with radiopharmaceuticals startup Aktis Oncology. Last year, the big pharma acquired Point Biopharma for $1.4 billion, gaining access to three radiopharmaceutical drug candidates that are currently in clinical development.
"Furthering our commitment to radiopharmaceutical therapies, this relationship provides access to novel GPCR targets and the discovery capabilities of Radionetics Oncology," said Jacob Van Naarden, Executive Vice President and President, Lilly Oncology.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.